15 Both technologies are based on the CRISPR-Cas system but utilize different CRISPR-associated proteins, Cas13 for SHERLOCK and Cas12a for DETECTR, to achieve their highly specific diagnostic ...
A pipeline for the analysis of CRISPR edited data. It allows the evaluation of the quality of gene editing experiments using targeted next generation sequencing (NGS) data (`targeted`) as well as the ...
Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the ...
Department of Chemical and Biomolecular Engineering (BK21 Four), Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
“For example, the most well-known of these immunotherapies only benefits 20 to 30% of patients.” When they delivered the Cas13 package into tumor microenvironments in mice, they found that it silenced ...
CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback